Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Female subjects between, and including, 18 and 45 years of age at the first vaccination;~2. Healthy subjects as established by medical history and history-oriented clinical examination;~3. Be able to understand and comply with the request of the protocol;~4. Without acute cervicitis;~5. Not pregnant;~6. Have intact cervix.~Exclusion Criteria:~1. Use of any investigational or non-registered product (drug or vaccine)within 30 days preceding the first vaccination, or plan to use during the study period;~2. Are using immunosuppressants;~3. Administration of immunoglobulin and/or any blood products within the three months preceding the first vaccination or planned administration during the study period;~4. Vaccinated of inactivated vaccine 14 days or attenuated vaccine 21 days before the enrollment;~5. Fever;~6. Concurrently participating another clinical trial;~7. Has received vaccines against HPV 16/18 ;~8. Immunodeficient;~9. History of allergic disease;~10. Serious medical disorders;~11. Blood coagulation disorders;~12. Epilepsy;~13. Unable to comply with protocol due to the mental illness;~14. Visible Condyloma;~15. Pregnant or breast-feeding women;~16. vergins;~17. Have more than 4 sexual partners.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- HPV vaccine (Type: EXPERIMENTAL): This dosage contains 40μg HPV 16 virus-like particle antigen and 20μg HPV 18 virus-like particle antigen adsorbed in alum-adjuvant
- HEV vaccine (Type: PLACEBO_COMPARATOR): commercialized HEV vaccine which contains 30μg HEV antigen adsorbed in alum-adjuvant

Based on this trial design, predict the completion outcome and termination type (if applicable).